(NASDAQ: AQST) Aquestive Therapeutics's forecast annual revenue growth rate of 33.79% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.25%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.92%.
Aquestive Therapeutics's revenue in 2025 is $44,132,000.On average, 4 Wall Street analysts forecast AQST's revenue for 2025 to be $3,959,526,928, with the lowest AQST revenue forecast at $1,866,826,447, and the highest AQST revenue forecast at $5,075,933,022. On average, 5 Wall Street analysts forecast AQST's revenue for 2026 to be $6,073,767,713, with the lowest AQST revenue forecast at $3,149,272,393, and the highest AQST revenue forecast at $7,449,355,535.
In 2027, AQST is forecast to generate $11,098,941,405 in revenue, with the lowest revenue forecast at $8,735,790,426 and the highest revenue forecast at $14,659,374,345.